Clinical trial · Interventional

Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma

Serplulimab Combined With Anti-VEGF Antibody and Platinum-based Chemotherapy in Treat-naive EGFR/ALK-negative Advanced Lung Adenocarcinoma, a Single Arm Clinical Trail

NCT05675033CI-TRIAL-00063076unknownPhase 2ClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

In order to further evaluate the efficacy of immunotherapy combined with antivascular therapy in the real world, we used Serpluimab combined with Bevacizumab and platinum-based chemotherapy in previously untreated EGFR/ALK-negative advanced non-squamous NSCLC patients, to evaluate the efficacy and safety of this regimen.

Conditions

Conditions (4)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Lung Adenocarcinoma	Lung Adenocarcinoma	ONTOLOGY_EXACT	0.98
PD-1 Inhibitor	—	UNRESOLVED	—
Stage IV Non-small Cell Lung Cancer	Lung Non-Small Cell Carcinoma	CURATED_BROADER	0.78
VEGF	—	UNRESOLVED	—

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
Serplulimab and Bevacizumab injection	Drug	—	UNRESOLVED

Design

Arms and outcomes

Arms (1)

type
OTHER
label
study arm
description
This is a single arm study.
interventionNames
1. Drug: Serplulimab and Bevacizumab injection

Primary outcomes (1)

measure
PFS
timeFrame
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
description
progression-free survival

Secondary outcomes (3)

measure
ORR
timeFrame
up to 12 months
description

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 18 Years
Maximum age: 75 Years

Show eligibility criteria text

Inclusion Criteria:

* Fully understood this study and voluntarily signed the informed consent form (ICF);

  -≥ 18 years and ≤ 75 years old;
* ECOG score 0-1;
* Non-squamous NSCLC;
* stage IV;
* EGFR and ALK negative;
* Treatment-naive;
* According to RECIST1.1 criteria, there are measurable or evaluable lesions.

Exclusion Criteria:

* Tumor histology or cytology confirmed that it was associated with squamous cell carcinoma or small cell lung cancer;
* Patients with severe organ dysfunction were indicated by examination, Exclude subjects with any active, known or suspected autoimmune diseases;
* The estimated survival time is less than 3 months.

References

Publications (0)

Data not yet available

No reference posted for this study.